Allergo Journal International最新文献

{"title":"Individuals with a history of allergic disease experience immunogenic side effects of vaccination more frequently","authors":"Valeria Hernández Guerrero,&nbsp;Julia Kurz,&nbsp;Urte Joseph,&nbsp;Christian Möbs,&nbsp;Oliver Pfaar,&nbsp;Georgios Chatzis,&nbsp; Wolfgang Pfützner","doi":"10.1007/s40629-026-00372-0","DOIUrl":"10.1007/s40629-026-00372-0","url":null,"abstract":"<div><h3>Background</h3><p>Adverse reactions to vaccines are common, but the nature and severity vary among individuals. This study describes vaccine reactions following vaccination with the coronavirus disease 2019 (COVID-19) mRNA vaccine Comirnaty® (Bretovameran, BioNTech Manufacturing, Mainz, Germany) and the vector-based vaccine Vaxzevria® (ChAdOx1‑S, AstraZeneca, Cambridge, UK). Particular focus was placed on the pattern of reactions in individuals with and without allergies or atopic diseases. Furthermore, the study investigated whether gender- or age-specific differences were discernible.</p><h3>Hypothesis</h3><p>The type and frequency of immunogenic vaccine reactions differ depending on individual, potentially predisposing factors such as pre-existing allergies, atopic status, or age and gender.</p><h3>Methods</h3><p>Employees who received their first vaccination with the Comirnaty® or Vaxzevria® vaccines from the occupational health service of the University Hospital Marburg during the COVID-19 pandemic between December 27, 2020, and April 23, 2021 were given an anonymous questionnaire. Information was obtained regarding the occurrence of immunogenic and allergic vaccine reactions, as well as age, gender, known allergies, and pre-existing atopic conditions.</p><h3>Results</h3><p>In all, 74.8% of vaccinated employees (<i>n</i> = 2845) participated in the study. Both COVID-19 vaccines administered showed a high incidence (70.6%) of local reactions and a comparatively lower frequency of systemic immune reactions such as fatigue (45.6%), headaches (35.1%), and muscle aches (27.1%). The most common side effects were pain at the injection site, fatigue, headaches, muscle aches, and joint pain. Individuals with a history of allergies and/or atopic diseases developed immunogenic local or systemic reactions significantly more frequently. Female and younger people (aged 18–34) were more likely to develop systemic reactions, while male participants were more likely to experience local vaccine side effects. No life-threatening side effects, particularly no anaphylaxis, were observed in connection with the vaccination.</p><h3>Conclusion</h3><p>Individuals with allergies and atopic conditions appear to notice immunogenic reactions more frequently following vaccination. Possible reasons could include a specific immunoreactive predisposition or subjective expectations. The pattern of vaccine reactions may vary by gender and age.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 4","pages":"109 - 115"},"PeriodicalIF":0.0,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-026-00372-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148141737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute generalized exanthematous pustulosis induced by iodinated contrast media","authors":"Alessandra Chiei Gallo MD,&nbsp;Chiara Ghelli,&nbsp;Alice Botta,&nbsp;Matteo Cavara,&nbsp;Christian Paolo Ratti,&nbsp;Eleonora Bono,&nbsp;Luca Carsana,&nbsp;Lea Caron,&nbsp;Enrico Iemoli,&nbsp;Valeria Ortolani","doi":"10.1007/s40629-026-00371-1","DOIUrl":"10.1007/s40629-026-00371-1","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 6","pages":"203 - 205"},"PeriodicalIF":0.0,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148927240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term maintenance of disease control in recalcitrant atopic and non-atopic chronic hand or hand-and-foot eczema after dupilumab treatment de-escalation in clinical practice","authors":"Irena Angelova-Fischer,&nbsp;Franziska Adlbrecht,&nbsp;Wolfram Hötzenecker","doi":"10.1007/s40629-026-00370-2","DOIUrl":"10.1007/s40629-026-00370-2","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 4","pages":"132 - 135"},"PeriodicalIF":0.0,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-026-00370-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148141738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-dose subcutaneous immunotherapy for pediatric house dust mite allergy","authors":"Yehonatan Pasternak,&nbsp;Iris Greenbaum,&nbsp;Shirley Sarig Epstein,&nbsp;Yoram Faitelson,&nbsp;Avi Beigelman","doi":"10.1007/s40629-026-00366-y","DOIUrl":"10.1007/s40629-026-00366-y","url":null,"abstract":"<div><h3>Background</h3><p>Pediatric allergic rhinitis (AR) caused by house dust mite (HDM) is common and may be treated with subcutaneous allergen immunotherapy (SCIT). However, the optimal maintenance dose in children remains unclear.</p><h3>Methods</h3><p>We conducted a cross-sectional comparative study among pediatric patients treated with low-dose (50 AU) versus standard-dose (500 AU) HDM SCIT. The Total Nasal Symptom Score (TNSS) and Total Medication Score (TMS) were assessed.</p><h3>Results</h3><p>Among 71 patients, 32 received low-dose and 39 received standard-dose SCIT. The two groups had comparable TNSS and TMS (TNSS: 5.59 vs. 5.35; TMS: 1.68 vs. 1.23, respectively).</p><h3>Conclusion</h3><p>Low-dose HDM SCIT may provide symptom control comparable to standard-dose SCIT in children, with potential for fewer systemic reactions.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 7","pages":"263 - 265"},"PeriodicalIF":0.0,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-026-00366-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149230775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic reaction to peach in a patient sensitized to Pru p 7 and Pru p 4: possible synergistic role of alcohol and gibberellin-regulated protein","authors":"Roberta Berretti,&nbsp;Nicole Peli,&nbsp;Luca Trianda,&nbsp;Francesco Bortoli,&nbsp;Tommaso Fasano,&nbsp;Alda Tiziana Scacchetti","doi":"10.1007/s40629-026-00369-9","DOIUrl":"10.1007/s40629-026-00369-9","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 5","pages":"168 - 170"},"PeriodicalIF":0.0,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148433533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Position paper on the documentation of biologic therapies for severe asthma","authors":"Ludger Klimek,&nbsp;Roland Buhl,&nbsp;Randolf Brehler,&nbsp;Eckard Hamelmann,&nbsp;Marcus Joest,&nbsp;Kristin aufm Kampe,&nbsp;Stephanie Korn,&nbsp;Sabine Lampert,&nbsp;Norbert Mülleneisen,&nbsp;Christian Taube,&nbsp;Jordis Trischler,&nbsp;Christian Vogelberg,&nbsp;Florian Schmitz,&nbsp; Marek Lommatzsch","doi":"10.1007/s40629-026-00368-w","DOIUrl":"10.1007/s40629-026-00368-w","url":null,"abstract":"<div><h3>Background</h3><p>Biologics are the first-line treatment for patients with severe, inadequately controlled asthma. They can lead to a significant reduction in (or even complete avoidance of) exacerbations, a reduction in the need for systemic glucocorticoids with their many side effects, and a marked improvement in asthma control and lung function in severe asthma. Due to the high annual costs of biologic therapy, there is legitimate interest among health insurances in guideline- and approval-compliant as well as cost-effective use of biologics in severe asthma. On the other hand, there is also legitimate interest among treating physicians in prescribing these biologics without risk of insurer repayment demands.</p><h3>Methodology</h3><p> Using an analysis of the literature and regulatory approvals, the evidence for treatment with currently approved biologics for severe asthma—omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab, and depemokimab— was documented, and supplemented by the clinical experiences of the authors.</p><h3>Results</h3><p>Based on the guideline recommendations and approvals, recommendations are made for the use of the aforementioned biologics in the German healthcare system. In a joint effort by various professional associations (AeDA, DGP, BdP, GAN, DGAKI, GPP, GPA), documentation forms were created for all biologics approved for severe asthma, which can serve as a basis for documentation. Forms were developed both for the initiation of biologic therapy and for the documentation of biologic treatment responses in severe asthma.</p><h3>Conclusion</h3><p>The new documentation forms concisely summarize all key points related to biologic prescription in severe asthma on a single page, serving both to ensure guideline-compliant and approval-compliant prescription and to avoid drug repayment demands.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 3","pages":"65 - 76"},"PeriodicalIF":0.0,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-026-00368-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147734930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutritional strategies and alternative protein sources for individuals with oilseed allergies: a narrative review","authors":"Elif Nur Çakar Dietitian MSc (Cont.),&nbsp; Seda Çiftçi","doi":"10.1007/s40629-026-00367-x","DOIUrl":"10.1007/s40629-026-00367-x","url":null,"abstract":"<div><p>Food allergies are a growing global health concern, with oilseed allergies particularly significant due to their association with severe and potentially life-threatening reactions. The prevalence of oilseed allergies is increasing worldwide, affecting children and adults alike. Common allergenic oilseeds include peanuts, walnuts, almonds, cashews, pistachios, sesame, and, in some regions, hazelnuts and sunflower seeds. Although these foods are rich in protein, healthy fats, and micronutrients, they can trigger serious reactions even at trace levels. Symptoms range from mild skin manifestations to anaphylaxis, complicating diagnosis and management. Diagnosis typically involves dietary history, skin prick tests, serum-specific immunoglobulin E analysis, elimination diets, and oral food challenges. Strict avoidance remains the main management strategy, but maintaining adequate protein intake is essential. Alternative sources such as legumes, cereals, microalgae, edible fungi, and precision fermentation products offer nutritionally adequate and lower-allergen options. Advances in processing further improve protein functionality and safety, supporting both individual nutrition and food system sustainability.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 3","pages":"77 - 86"},"PeriodicalIF":0.0,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147734898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type I sensitization profiles in patients with spice syndromes","authors":"Benjamin Walz,&nbsp;Vincent Walter,&nbsp;Laura Schmidberger,&nbsp;Manfred Kneilling,&nbsp;Jörg Fischer,&nbsp;Sebastian Volc","doi":"10.1007/s40629-026-00364-0","DOIUrl":"10.1007/s40629-026-00364-0","url":null,"abstract":"<div><h3>Background</h3><p>Allergies to spices have not been adequately researched to date, but they are becoming increasingly important in allergology. The clinical spectrum ranges from mild symptoms to anaphylaxis. Spice allergies can occur as cross-reactions in the form of spice syndromes if type I sensitization to herb pollen is present. The aim of this study was to precisely characterize cross-reactive spice syndromes and their sensitization profiles. Particular attention was paid to the manifestation of mugwort–(celery)–spice syndrome, mugwort–tropical fruit syndrome, and latex–tropical fruit syndrome.</p><h3>Methods</h3><p>We performed a retrospective evaluation of 64 patients who were examined for spice syndromes at the University Dermatology Clinic in Tübingen between 2019 and 2024. Diagnoses and cutaneous and serological evidence of specific IgE antibodies were recorded.</p><h3>Results</h3><p>Patients with mugwort–(celery)–spice syndrome in our cohort were characterized by frequent sensitization to aeroallergens, especially ragweed and mugwort. Serological sensitization to PR10 homologues was common, while sensitization to profilins and to the mugwort major allergen Art v 1 (PR12) was less common. In patients with mugwort–tropical fruit syndrome, sensitization to herbs was particularly common, with all patients testing positive for the mugwort major allergen Art v 1. There was more frequent cutaneously detectable sensitization to labiate plants in mugwort–(celery)–spice syndrome compared to mugwort–tropical fruit syndrome, while sensitization to umbelliferous plants and other spices occurred with similar frequency in both groups. Only one patient had latex–tropical fruit syndrome.</p><h3>Conclusion</h3><p>The results highlight the complex immunological cross-reactivities between pollen and plant allergens and may contribute to a more comprehensive understanding of spice syndromes.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 3","pages":"87 - 97"},"PeriodicalIF":0.0,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-026-00364-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147734928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral allergy syndrome due to beer yeast in patients consuming special beers but tolerating pilsner","authors":"Felix Quataert MD,&nbsp;Jan Gutermuth MD PhD,&nbsp;Martine Grosber MD PhD","doi":"10.1007/s40629-026-00365-z","DOIUrl":"10.1007/s40629-026-00365-z","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 4","pages":"136 - 138"},"PeriodicalIF":0.0,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148141727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of severe allergic reactions and anaphylaxis with an adrenaline nasal spray","authors":"Regina Treudler,&nbsp;Kirsten Beyer,&nbsp;Katharina Blümchen,&nbsp;Sunhild Gernert,&nbsp;Michael Gerstlauer,&nbsp;Eckard Hamelmann,&nbsp;Thilo Jakob,&nbsp;Ludger Klimek,&nbsp;Oliver Pfaar,&nbsp;Franziska Ruëff,&nbsp;Sabine Schnadt,&nbsp;Marc Schönherr,&nbsp;Sebastian Seurig,&nbsp;Christian Vogelberg,&nbsp;Dorothea Wieczorek,&nbsp;Margitta Worm,&nbsp; Eike Wüstenberg","doi":"10.1007/s40629-026-00363-1","DOIUrl":"10.1007/s40629-026-00363-1","url":null,"abstract":"<div><p>First-line therapy for a severe allergic reaction (anaphylaxis) is the administration of adrenaline, which, in an emergency, can be self-administered intramuscularly (i.m.) via an adrenaline autoinjector (AAI). Despite the known risk of anaphylaxis, AAIs are often not prescribed, not carried, not used, or used with delay in an emergency. Possible reasons for this include logistical issues (e.g., size and portability of the AAI), difficulties in recognizing symptoms that require the use of an AAI, lack of familiarity with the AAI application, and general fear of injections. Recently, an adrenaline nasal spray (ANS) for intranasal application of adrenaline has been authorized and introduced in Germany. Pharmacokinetic studies for ANS development in comparison with the i.m. injection using an AAI or manual injection (syringe and needle) resulted in comparable profiles. The simple use and small size of the ANS, the needle-free design, and the improved storage conditions can help reduce barriers to adrenaline administration for patients and other users. This may lead to an earlier administration of adrenaline in anaphylaxis treatment.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"35 2","pages":"38 - 44"},"PeriodicalIF":0.0,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-026-00363-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147383180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}